Peter Dull

7.3k total citations · 1 hit paper
88 papers, 4.4k citations indexed

About

Peter Dull is a scholar working on Epidemiology, Microbiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Peter Dull has authored 88 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Epidemiology, 65 papers in Microbiology and 13 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Peter Dull's work include Bacterial Infections and Vaccines (65 papers), Pneumonia and Respiratory Infections (62 papers) and Influenza Virus Research Studies (31 papers). Peter Dull is often cited by papers focused on Bacterial Infections and Vaccines (65 papers), Pneumonia and Respiratory Infections (62 papers) and Influenza Virus Research Studies (31 papers). Peter Dull collaborates with scholars based in United States, United Kingdom and Italy. Peter Dull's co-authors include Daniela Toneatto, Lisa Bedell, George R. Siber, Andrew Fioré-Gartland, Stanley A. Plotkin, Donna M. Ambrosino, David Goldblatt, Roman Prymula, Kristen Earle and Peter B. Gilbert and has published in prestigious journals such as The Lancet, JAMA and Applied Physics Letters.

In The Last Decade

Peter Dull

86 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence for antibody as a protective correlate for COVID-19 vaccines

2021 475 citations Donna M. Ambrosino, Andrew Fioré-Gartland et al. Vaccine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Dull United States	38	3.0k	2.6k	934	691	428	88	4.4k
James Watt United States	32	3.4k 1.1×	1.4k 0.5×	1.3k 1.3×	1.0k 1.5×	277 0.6×	93	5.2k
Nancy E. Messonnier United States	28	2.4k 0.8×	2.4k 0.9×	526 0.6×	395 0.6×	299 0.7×	46	3.3k
David W. Scheifele Canada	42	4.0k 1.3×	2.1k 0.8×	1.1k 1.2×	444 0.6×	262 0.6×	239	5.6k
Qiushui He Finland	38	3.5k 1.2×	3.4k 1.3×	991 1.1×	354 0.5×	445 1.0×	213	5.0k
Caroline Trotter United Kingdom	43	5.6k 1.9×	4.3k 1.6×	629 0.7×	506 0.7×	256 0.6×	143	6.8k
Thomas Cherian India	32	4.4k 1.5×	1.6k 0.6×	972 1.0×	617 0.9×	265 0.6×	106	6.1k
Kathleen Harriman United States	34	2.2k 0.7×	1.1k 0.4×	2.1k 2.2×	757 1.1×	441 1.0×	70	4.4k
David P. Greenberg United States	35	3.3k 1.1×	1.5k 0.6×	953 1.0×	262 0.4×	399 0.9×	98	4.4k
Birger Trollfors Sweden	39	3.2k 1.1×	2.3k 0.9×	1.3k 1.3×	804 1.2×	214 0.5×	200	5.4k
Paola Stefanelli Italy	29	1.8k 0.6×	1.9k 0.7×	811 0.9×	172 0.2×	250 0.6×	179	3.1k

Countries citing papers authored by Peter Dull

Since Specialization

Citations

This map shows the geographic impact of Peter Dull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dull more than expected).

Fields of papers citing papers by Peter Dull

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dull. The network helps show where Peter Dull may publish in the future.

Co-authorship network of co-authors of Peter Dull

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Dull. A scholar is included among the top collaborators of Peter Dull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Dull. Peter Dull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sierra, Mónica S., Peter Dull, Rolando Herrero, et al.. (2025). Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT). Vaccine. 50. 126841–126841.

Goldblatt, David, Andrew Fioré-Gartland, Marina Johnson, et al.. (2021). Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 40(2). 306–315. 87 indexed citations

Walker, Richard I. & Peter Dull. (2017). Combination vaccine strategies to prevent enteric infections. Vaccine. 35(49). 6790–6792. 17 indexed citations

Heyderman, Robert S., Shabir A. Madhi, Neil French, et al.. (2016). Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. The Lancet Infectious Diseases. 16(5). 546–555. 84 indexed citations

Snape, Matthew D., Merryn Voysey, Adam Finn, et al.. (2016). Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. The Pediatric Infectious Disease Journal. 35(4). e113–e123. 27 indexed citations

Block, Stan L., Bikash Verma, Fang Xie, et al.. (2015). Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination. Vaccine. 33(18). 2175–2182. 16 indexed citations

Vesikari, Timo, Roman Prymula, Elizabeth Merrall, et al.. (2015). Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine. 33(32). 3850–3858. 17 indexed citations

Block, Stan L., Leszek Szenborn, Teresa Jackowska, et al.. (2015). A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine. 33(21). 2500–2510. 40 indexed citations

Blanchard‐Rohner, Géraldine, Matthew D. Snape, Dominic F. Kelly, et al.. (2013). Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom. The Pediatric Infectious Disease Journal. 32(7). 768–776. 14 indexed citations

10.

Madhi, Shabir A., Ziyaad Dangor, Paul T. Heath, et al.. (2013). Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 31. D52–D57. 95 indexed citations

11.

Finn, Adam, Gianni Bona, Susanna Esposito, et al.. (2012). Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. JAMA. 307. 4 indexed citations

12.

Khatami, Ameneh, Matthew D. Snape, Elizabeth G. Davis, et al.. (2012). Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 30(18). 2831–2838. 24 indexed citations

13.

Gill, Christopher, et al.. (2010). Antibody persistence 22 months after vaccination of adolescents with the Novartis investigational meningococcal ACWY-CRM197 conjugate vaccine or Menactra®. International Journal of Infectious Diseases. 14. e447–e447. 1 indexed citations

14.

Gill, Christopher, et al.. (2010). Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Human Vaccines. 6(11). 881–887. 75 indexed citations

15.

Perrett, Kirsten P., Matthew D. Snape, Karen Ford, et al.. (2009). Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. The Pediatric Infectious Disease Journal. 28(3). 186–193. 52 indexed citations

16.

Perrett, Kirsten P., Tessa M. John, David Pace, et al.. (2008). Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. JAMA. 299. 6 indexed citations

17.

Snape, Matthew D., Kirsten P. Perrett, Karen Ford, et al.. (2006). ImmunogenicityofaTetravalentMeningococcal Glycoconjugate Vaccine in Infants. 1 indexed citations

18.

Quinn, Conrad P., Peter Dull, Vera Semenova, et al.. (2004). Immune Responses toBacillus anthracisProtective Antigen in Patients with Bioterrorism‐Related Cutaneous or Inhalation Anthrax. The Journal of Infectious Diseases. 190(7). 1228–1236. 101 indexed citations

19.

Dull, Peter, J. Abdelwahab, Cláudio Tavares Sacchi, et al.. (2004). Neisseria meningitidisSerogroup W‐135 Carriage among US Travelers to the 2001 Hajj. The Journal of Infectious Diseases. 191(1). 33–39. 33 indexed citations

20.

Kuehnert, Matthew J., Timothy J. Doyle, Holly A. Hill, et al.. (2003). Clinical Features that Discriminate Inhalational Anthrax from Other Acute Respiratory Illnesses. Clinical Infectious Diseases. 36(3). 328–336. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact